Navigation Links
Northwest Secures US$1.65 Million Debt Financing
Date:11/6/2008

logies: dendritic cell-based vaccines, and therapeutic antibodies. The Company is currently conducting a large clinical trial in Glioblastoma multiforme, which is designed and powered to serve as a pivotal trial. The Company has also received clearance from the FDA for a large Phase III trial in prostate cancer, and clearance from the FDA for Phase I trials in five other cancers. The Company has started, and is currently enrolling patients in, a Phase I/II trial with DCVax(R) for recurrent ovarian cancer. The Company also has a second technology platform, involving monoclonal antibodies to CXCR4, which is at the late pre-clinical development stage.

For further information, please visit the company web site at http://www.nwbio.com.

Disclaimer

Statements made in this news release that are not historical facts, including statements concerning the Company's plans to move its programs forward, either in the U.S. or outside the U.S., statements regarding the Company's clinical trials and other business development activities, and statements regarding its fundraising activities, are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Words such as "expects," "believes," "intends," and similar expressions are intended to identify forward-looking statements. Actual results may differ materially from those projected in any forward-looking statement. Specifically, there are a number of important factors that could cause actual results to differ materially from those anticipated, such as risks and uncertainties regarding the Company's ability to secure additional financing or raise additional capital, risks related to the Company's ability to enroll patients in its clinical trials and complete the trials on a timely basis, the uncertainty of the clinical trials process, uncertainties about the Company's ability to deliver its products to patients and charge p
'/>"/>

SOURCE Northwest Biotherapeutics, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Northwest Biotherapeutics, Inc. Announces Appointment of Chief Financial Officer
2. Lonza Withdraws Majority of Claims in Patent Lawsuit Against Northwest Biotherapeutics
3. Cell Therapeutics, Inc. (CTI) to Present at 7th Annual WBBA Invest Northwest Conference
4. Cell Therapeutics, Inc. (CTI) Invest Northwest Presentation to be Webcast
5. Northwest Secures US$4.0 Million in Debt Financing
6. Nikon Instruments Opens New Imaging Center at Northwestern University
7. Northwestern chemist investigates lost reds in Homer painting
8. Northwest Biotherapeutics to Present at Next Generation Vaccine Conference
9. Northwestern chemists take gold, mass-produce Beijing Olympic logo
10. Northwest Secures US$1.0 Million Debt Financing
11. Microchip Biotechnologies, Inc. Secures Exclusive License to Use New University of Alberta Technology for Developing Microfluidic Devices
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/23/2014)... , Sept. 23, 2014 /PRNewswire/ - Portage Biotech ... Securities Exchange: PBT.U), is pleased to announce that ... has added two more  consultants to its team ... PPL-003 uses a new proprietary cell permeable peptide ... its anti-inflammatory cargo into the eye. ...
(Date:9/23/2014)... , September 23, 2014 ... Closed System Transfer     Devices  (CSTD) ... partnership with Taiwanese distributor MedFront Medical Technology Corporation.  Equashield,s leading ... Taiwan , China ... the company continues to expand globally, and throughout ...
(Date:9/23/2014)... New York (PRWEB) September 23, 2014 ... from around the globe will convene at ... International Conference, to be held October 26-28 ... in evidence-based research and practice in individualized ... physicians, scientists, researchers, nurses, psychologists, nutritionists, naturopaths, ...
(Date:9/22/2014)... 2014 Pearl's Premium Ultra Low Maintenance ... tolerant grass seed this week with the release of ... coincides with the fact that it is time to ... believe. , As of the date 6/4/13, Pearl's ... by industry experts and the media including: The ...
Breaking Biology Technology:Portage Announces New Consultants for its PPL-003 Development Programs 2Portage Announces New Consultants for its PPL-003 Development Programs 3Portage Announces New Consultants for its PPL-003 Development Programs 4Equashield Enters Taiwan Following Expansion to Australia, Japan, China 2International Medical Experts to Discuss Latest Integrative Oncology Research and Its Translation to Personalized Clinical Care at 11th International Conference of SIO 2International Medical Experts to Discuss Latest Integrative Oncology Research and Its Translation to Personalized Clinical Care at 11th International Conference of SIO 3Pearl's Premium Ultra Low Maintenance Lawn Seed Announces A Major Breakthrough In Drought Tolerant Grass Seed 2
... BRISBANE, Australia and SEATTLE, Feb. 24 Implicit,Bioscience ... antibody IC14 from Eli Lilly and Company. Implicit ... to Lilly. Lilly will also,receive a royalty on ... "Implicit Bioscience brings substantial expertise and passion to ...
... Feb. 24 Nektar Therapeutics,(Nasdaq: NKTR ... fourth quarter and,year ended December 31, 2008. , ... year for Nektar," said Howard W. Robin,President and ... unique polymer,conjugation chemistry platform, we advanced numerous proprietary ...
... proteinTHOUSAND OAKS, Calif., Feb. 24 Bone Biologics, Inc. ... Aragen Bioscience, has completed development of a recombinant cell ... protein. Bone Biologics has been developing the protein as ... years of research in the lab performed by the ...
Cached Biology Technology:Implicit Licenses Clinical Stage Antibody Program From Lilly 2Implicit Licenses Clinical Stage Antibody Program From Lilly 3Nektar Therapeutics Reports Fourth Quarter and Year-End 2008 Financial Results 2Nektar Therapeutics Reports Fourth Quarter and Year-End 2008 Financial Results 3Nektar Therapeutics Reports Fourth Quarter and Year-End 2008 Financial Results 4Nektar Therapeutics Reports Fourth Quarter and Year-End 2008 Financial Results 5Nektar Therapeutics Reports Fourth Quarter and Year-End 2008 Financial Results 6Nektar Therapeutics Reports Fourth Quarter and Year-End 2008 Financial Results 7Nektar Therapeutics Reports Fourth Quarter and Year-End 2008 Financial Results 8Nektar Therapeutics Reports Fourth Quarter and Year-End 2008 Financial Results 9Bone Biologics Announces UCB-1 (NELL-1) Bone Growth Protein Production Process With Aragen Biosciences 2
(Date:9/22/2014)... Manufacturing biofuels from food crop by-products such as straw ... work of scientists in the UK and France. ... Research Council (BBSRC) have discovered variant straw plants whose ... biofuels, but which are not significantly smaller or weaker ... ease pressure on global food security as biofuels from ...
(Date:9/22/2014)... their own "antifreeze" proteins to survive in the ... effect, researchers report: The protein-bound ice crystals that ... temperatures warm. , The finding is reported ... of Sciences . , "We discovered what appears ... of antifreeze proteins in Antarctic notothenioid fishes," said ...
(Date:9/22/2014)... of seven institutions in the country selected by ... this year,s BEST Award a $2 million ... most promising biomedical sciences graduate trainees to career ... they have traditionally taken. , The award funds ... Biomedical Scientists (iJOBs) program. It includes courses, seminars, ...
Breaking Biology News(10 mins):Plant variants point the way to improved biofuel production 2Study: Antifreeze proteins in Antarctic fishes prevent freezingand melting 2Study: Antifreeze proteins in Antarctic fishes prevent freezingand melting 3Rutgers receives $2 million grant to prepare biomedical students for roles in industry 2Rutgers receives $2 million grant to prepare biomedical students for roles in industry 3
... relatively common to come across petrol stations surrounded by houses, ... (UM) have studied the effects of contamination at petrol stations ... in buildings less than 100 metres from the service stations. ... increases the risk of cancer have been recorded at ...
... has been awarded a $2.3 million grant by the ... focusing on developing a novel stem cell based therapy ... studying human induced pluripotent stem (iPS) cells derived from ... in the lab and investigate the role of inflammation ...
... not-so-distant evolutionary past, stress often meant imminent danger, ... of our body,s stress response is to stock-pile ... Unit (MMPU), a collaboration between the European Molecular ... University of Heidelberg Medical Centre, have discovered how ...
Cached Biology News:Petrol stations pollute their immediate surroundings 2Stem cell leader awarded $2.3 million grant for Parkinson's 2Blood-clotting protein linked to cancer and septicemia 2Blood-clotting protein linked to cancer and septicemia 3
This monoclonal antibody specifically recognizes Y. pestiscapsular F1 antigen. It does not cross-react with Y. pseudotuberculosisor Y. enterocolitica....
...
Rabbit polyclonal to JNK1 (phospho T183 + Y185) ( Abpromise for all tested applications). entrezGeneID: 5599 SwissProtID: P45983...
Permeabilization Solution, 5X...
Biology Products: